Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality

JAMA

Volumn 304, Issue 9, 2010, Pages 967-975

  Domchek, Susan M ^a,b   Friebel, Tara M ^b   Singer, Christian F ^c   Gareth Evans, D ^d   Lynch, Henry T ^e   Isaacs, Claudine ^f   Garber, Judy E ^g   Neuhausen, Susan L ^h   Matloff, Ellen ⁱ   Eeles, Rosalind ^j   Pichert, Gabriella ^k   Van T'veer, Laura ^l   Tung, Nadine ^m   Weitzel, Jeffrey N ⁿ   Couch, Fergus J ^o   Rubinstein, Wendy S ^p,q   Ganz, Patricia A ^r   Daly, Mary B ^s   Olopade, Olufunmilayo I ^q   Tomlinson, Gail ^t   Schildkraut, Joellen ^u   Blum, Joanne L ^v   Rebbeck, Timothy R ^a,b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d St Mary's Hospital   (United Kingdom)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ YALE UNIVERSITY   (United States)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o MAYO CLINIC   (United States)

^p NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^q UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s FOX CHASE CANCER CENTER   (United States)

^t UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^u DUKE UNIVERSITY MEDICAL CENTER   (United States)

^v BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; ASSOCIATION; BRCA 1 GENE; BRCA 2 GENE; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; GENE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NORTH AMERICA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; ADOLESCENT; BREAST TUMOR; CAUSE OF DEATH; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; OVARIECTOMY; OVARY TUMOR; RISK; TUMOR SUPPRESSOR GENE; UTERINE TUBE;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CAUSE OF DEATH; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PROSPECTIVE STUDIES; RISK;

EID: 77956193440     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1237     Document Type: Article

References (38)

1. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
2. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-1408.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333.
4. Ford D, Easton DF, Stratton M, et al; The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3):676-689.
5. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83(10):1301-1308.
6. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8(12):3776-3781.
7. Rebbeck TR, Lynch HT, Neuhausen SL, et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-1622.
8. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475-1479.
9. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.
10. Finch A, Beiner M, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185-192.
11. Kramer JL, Velazquez IA, Chen BE, et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005;23(34):8629-8635.
12. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Lancet Oncol. 2006;7(3):223-229.
13. Chang-Claude J, Andrieu N, Rookus M, et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2007;16(4):740-746. (Pubitemid 46650576)
14. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2005;23(30):7491-7496.
15. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer. J Clin Oncol. 2008;26(8):1331-1337.
16. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations. J Natl Cancer Inst. 2003;95(14):1072-1078.
17. Shah P, Rosen M, Stopfer J, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2009;118(3):539-546.
18. Lin DYWL. Robust inferences for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
19. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25(20):2921-2927.
20. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164.
21. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(6):1055-1062. (Pubitemid 41095038)
22. Parker WH, Jacoby V, Shoupe D, Rocca W. Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl). 2009;5(5):565-576.
23. Parker WH, Manson JE. Oophorectomy and cardiovascular mortality: is there a link? Menopause. 2009;16(1):1-2.
24. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074-1083.
25. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008;70(3):200-209.
26. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol. 2009;113(5):1027-1037.
27. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer. Lancet. 2004;364(9437):858-868.
28. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer. J Clin Oncol. 2005;23(25):5973-5982.
29. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-2335. (Pubitemid 41115389)
30. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24(16):2437-2443.
31. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer. J Clin Oncol. 2002;20(9):2310-2318.
32. Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women. Lancet Oncol. 2006;7(10):821-828.
33. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
34. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602.
35. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2005;23(31):7804-7810.
36. Klaren HM, van't Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst. 2003;95(13):941-947.
37. Hartmann LC, Degnim A, Schaid DJ. Prophylactic mastectomy for BRCA1/2 carriers. J Clin Oncol. 2004;22(6):981-983.
38. Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy. J Med Genet. 2009;46(4):254-258.